Axon Enterprise, Inc (NASDAQ:AXON) Given Average Rating of “Moderate Buy” by Brokerages

Axon Enterprise, Inc (NASDAQ:AXON) has earned an average rating of “Moderate Buy” from the eighteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $802.7143.

A number of equities research analysts have issued reports on the company. Barclays reduced their price target on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. JMP Securities reaffirmed a “market outperform” rating and issued a $825.00 target price on shares of Axon Enterprise in a report on Monday, September 29th. Needham & Company LLC reiterated a “buy” rating and set a $870.00 price target on shares of Axon Enterprise in a report on Wednesday, September 24th. Morgan Stanley reduced their price objective on shares of Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Cowen reaffirmed a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $594.20 on Tuesday. The firm has a 50 day moving average of $608.22 and a two-hundred day moving average of $707.67. The stock has a market capitalization of $46.89 billion, a PE ratio of 188.04, a P/E/G ratio of 136.47 and a beta of 1.40. The company has a quick ratio of 2.89, a current ratio of 3.12 and a debt-to-equity ratio of 0.57. Axon Enterprise has a 52 week low of $469.24 and a 52 week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.46). The company had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The firm’s revenue was up 30.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.45 earnings per share. On average, research analysts predict that Axon Enterprise will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Brittany Bagley sold 2,000 shares of the firm’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $580.00, for a total transaction of $1,160,000.00. Following the sale, the chief financial officer owned 103,501 shares of the company’s stock, valued at approximately $60,030,580. This trade represents a 1.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeri Williams sold 100 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $550.63, for a total value of $55,063.00. Following the sale, the director owned 1,316 shares of the company’s stock, valued at approximately $724,629.08. The trade was a 7.06% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 64,406 shares of company stock valued at $38,521,038 over the last 90 days. 4.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Axon Enterprise

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AXON. Brighton Jones LLC purchased a new position in shares of Axon Enterprise in the 4th quarter valued at $480,000. Vestmark Advisory Solutions Inc. boosted its stake in Axon Enterprise by 97.2% in the first quarter. Vestmark Advisory Solutions Inc. now owns 1,262 shares of the biotechnology company’s stock valued at $664,000 after acquiring an additional 622 shares in the last quarter. Kovitz Investment Group Partners LLC grew its holdings in shares of Axon Enterprise by 166.0% during the first quarter. Kovitz Investment Group Partners LLC now owns 2,875 shares of the biotechnology company’s stock worth $1,512,000 after purchasing an additional 1,794 shares during the last quarter. Horizon Investments LLC increased its position in shares of Axon Enterprise by 6.0% during the first quarter. Horizon Investments LLC now owns 1,042 shares of the biotechnology company’s stock worth $548,000 after purchasing an additional 59 shares in the last quarter. Finally, Cresset Asset Management LLC increased its position in shares of Axon Enterprise by 5.7% during the first quarter. Cresset Asset Management LLC now owns 1,833 shares of the biotechnology company’s stock worth $964,000 after purchasing an additional 99 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.